BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
ATV/Ritonavir Nevirapine Interaction (USPAC)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00162149
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
Study of Dasatinib in Patients With Advanced Solid Tumors
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00162214
- Locations
- 🇺🇸
Lee S. Rosen M.D., Santa Monica, California, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2008-08-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00162448
- Locations
- 🇺🇸
Local Institution, Columbus, Ohio, United States
Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT00162292
- Locations
- 🇲🇽
Local Institution, Leon, Guanajuato, Mexico
🇺🇸Delray Research Associates, Delray Beach, Florida, United States
🇺🇸Phase Iii Clinical Research, Fall River, Massachusetts, United States
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
- Conditions
- Psoriasis, Moderate to Severe
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT00162253
- Locations
- 🇺🇸
Local Institution, Dallas, Texas, United States
PPAR-COMBO With Sulfonylurea
- Conditions
- Metabolics Diabetes Nos
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 534
- Registration Number
- NCT00162175
- Locations
- 🇬🇧
Local Institution, Swan Lane, United Kingdom
The Study of Abatacept in Combination With Etanercept
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 141
- Registration Number
- NCT00162279
- Locations
- 🇺🇸
Local Institution, Glendale, Wisconsin, United States
PPAR - Combination With Metformin
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 534
- Registration Number
- NCT00162240
- Locations
- 🇬🇧
Local Institution, Swan Lake, United Kingdom
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 248
- Registration Number
- NCT00162123
- Locations
- 🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸University Of Chicago, Chicago, Illinois, United States
🇺🇸Indiana Oncology Hematology Consultants, Indianapolis, Indiana, United States
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
- Conditions
- HIV Infections
- Interventions
- Drug: Atazanavir+ritonavirDrug: Lopinavir+ritonavir
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2010-02-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00135395
- Locations
- 🇵🇷
Local Institution, Santruce, Puerto Rico